INTRODUCTION
Upper tract urothelial carcinoma (UTUC) arises from the urothelial lining of the urinary tract from the renal calyces to the ureteral orifice. They comprise 10% of all renal tumors and 5% of all urothelial malignancies. [1] Transitional cell carcinomas (TCCs) are the most common primary tumor of UTUC. Although non-TCC such as squamous cell carcinoma (SCC), adenocarcinoma, small cell carcinoma (SmCC), and undifferentiated carcinomas are rare, but they exist. Chronic irritation and chronic infection of the upper tract are among the most common risk factors for the development of such rare tumors. [2] There are few case reports in the literature because of the rarity of the disease. Concurrently, there is a wide range of the incidence of non-TCC of the upper urinary tract (1.9-8%). [3] [4] [5] Thus, subsequent more studies are needed from single institutions to narrow the true range of incidence.
Even in the urinary bladder (UB) carcinoma which comprises about 95% of urothelial tumors, there is also a paucity of data in non-TCCs of the bladder with only a few studies. [6] [7] [8] The recommendations were for more case reporting to advance our understanding of these tumors and for a universal treatment algorithm.
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MATERIALS AND METHODS
After Institutional Review Board approval, we retrospectively reviewed our ongoing database for patients who were surgically treated for UTUC from 1983 to 2013. Patients with non-TCC at the final histopathology were selected for review.
Most of the patients were treated by standard radical open/laparoscopic nephroureterectomy with bladder cuff excision procedures. Renal-sparing surgeries were done in a few cases.
Surgical specimens were processed according to the standard pathological procedure. The tumor was staged according to the 1997 TNM classification, and the most traditional 3-tiered WHO grading system was used for pathological grading by different pathologists. [8] None of our patients received neoadjuvant or adjuvant chemotherapy.
The postoperative regimen in the first 2 years included a cystoscopy every 3 months and contrast-enhanced computed tomography (CT) every 6 months. From the 3 rd to 5 th year, a cystoscopy every 6 months and a CT annually; thereafter, clinical examination, urine analysis, and cytology were ordered annually. Frequency and percentage were used for categorical variables. Cancer-specific survival was estimated using KaplanMeier methods.
CASES
Squamous and/or glandular differentiation was reported with TCC in 33 (10%) patients, whereas 5 (1.6%) cases were found with pure non-TCC at the final pathology [ Figure 1 ].
One case had SmCC in the proximal ureter and another case was proved to be adenocarcinoma in pelvicalyceal system in a 77-year-old male, who died after 5 months. Three patients had SCC of the renal pelvis (RP), and two of them were treated with radical nephrectomy of renal masses [ Figures 2 and 3] . The clinical, histopathological characteristics and outcomes are listed in Table 1 . The cancer-specific survival for non-TCC cohort is markedly decreased (log-rank = 0.01) compared to TCC patients. None of them had intravesical recurrence.
DISCUSSION
Non-TCC is a rare tumor of the upper urinary tract. In our series, the incidence is 1.6% − that is close to what is reported by Busby et al. among 474 UTUC patients (1.9%). [4] However, Holmäng et al. reported 8% incidence for SCC only, 6%
were with pure SCC in their series. [3] Similarly, Li and Cheung reported 8% SCC among 144 patients. [2] We may contribute the wide range of the incidence of non-TCC in the literature to the subjective pathologic reporting with pure or mixed non-TCC histological types. We have 33 patients (11%) in our series with squamous and glandular differentiation reported with TCC; that is also similar to the incidence in a large multi-institutional study (14%) that enrolled more than 1600 patients. [9] Reporting these cases as pure SCC or adenocarcinoma may cause the difference in the incidence of non-TCC.
SmCC of the upper urinary tract is a neuroendocrine cell tumor. Positive staining for chromogranin A1, synaptophysin, and neuron-specific enolase confirm the diagnosis. Histopathologically, it is similar to their pulmonary counterpart with small, uniform cells with nuclear molding, scant cytoplasm, and nuclei containing finely dispersed chromatin [ Figure 4 ].
The case in our series was in the ureter, and that is in accordance to many published series. Ouzzane et al. reported two cases of SmCC; both were in the ureter.
Adenocarcinoma of the upper urinary tract is a rare tumor, comprising less than 0.5% of the UTUC. [4] It must be a pure adenocarcinoma with histopathological features of well-defined glands lined by typical cells with large nuclei and moderate amount of mucinous cytoplasm staining for carcinoembryonic antigen and mucin [ Figure 5 ].
Based on the published case reports, the cancer survival varies for patients with adenocarcinoma of the upper tract. Two cases, one in the RP and the other in the ureter died 5 and 125 months, respectively, after the treatment. [4] In another SCC is the most common among non-TCC type as it comprises 1-6% on non-TCC. [3, 5] Many risk factors may have a role in the pathogenesis of SCC: Chronic irritation, long-standing urinary obstruction, and renal stones. [2] Previous surgeries for renal stones, analgesic use, and radiotherapy were also considered as risk factors. [3] One of our patients had hydronephrosis and the other had multiple stones [ Figure 3 ]. SCC may be associated with paraneoplastic syndrome; [10] however, the laboratory workup of our patients did not show any abnormal results.
SCC may mimic renal parenchymal tumors in its radiologic criteria; two out of three patients in our series were operated by radical nephrectomy for renal parenchymal tumors.
Histopathologically, SCC is characterized by sheets of cells with well-defined cell borders, deeply eosinophilic cytoplasm, and features of keratin pearls [ Figure 6 ].
The three patients in our series had tumors in the RP and calyces; one also involved the upper part of the ipsilateral ureter. Similarly, 70% of SCC cases and among 808 patients with UTUC were in the RP. [3] Studies from UB carcinomas reflected the role of chronic irritation/infection in the pathogenesis of non-TCC. When the schistosomiasis was endemic in Egypt, the incidence of SCC and adenocarcinoma was reported to be 59% and 22%, respectively. [11] Non-TCC incidence is much different than what was reported from a systematic review from Europe and North America that reported the incidence of SCC, SmCC, and adenocarcinoma of 3-5%, 0.5-2%, and <0.5%, respectively. [6] Patients having such risk factors are advised to be counseled for possible development of non-TCC.
Surgery is still the treatment of choice for non-TCC, whereas radiotherapy and chemotherapy have little benefit. [2] Adjuvant chemotherapy was used in 11 patients; however, the median survival was only 5 months. [12] 
CONCLUSION
In our series, non-TCC of the upper urinary tract is rare (1.6%). It may exist with no known risk factors has a poor prognosis when compared to TCC, and it is seldom to have intravesical recurrences. New neoadjuvant and adjuvant therapies are hoped to improve the survival in such patients.
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